Linker Information
General Information of This Linker
| Linker ID |
LIN0SXPBU
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
BG based linker
|
|||||
| Linker Type |
Bioorthogonal reaction linker
|
|||||
| Antibody-Linker Relation |
Uncleavable
|
|||||
| Structure |
|
|||||
| Formula |
C18H38O10
|
|||||
| Isosmiles |
OCCOCCOCCOCCOCCOCCOCCOCCOCCO
|
|||||
| InChI |
InChI=1S/C18H38O10/c19-1-3-21-5-7-23-9-11-25-13-15-27-17-18-28-16-14-26-12-10-24-8-6-22-4-2-20/h19-20H,1-18H2
|
|||||
| InChIKey |
YZUUTMGDONTGTN-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
414.492
|
Polar area
|
114.3
|
||
|
Complexity
|
414.2464974
|
xlogp Value
|
-0.8962
|
|||
|
Heavy Count
|
28
|
Rot Bonds
|
25
|
|||
|
Hbond acc
|
10
|
Hbond Donor
|
2
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
BDC-1001 [Phase 2 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Patients with advanced metastatic HER2-expressing (IHC2/3+) or amplified solid tumors. Patients had received a median of 4 prior therapies.
|
||||
| Administration Dosage |
4 dose levels (0.15-5.00 mg/kg) every 3 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04278144 | Clinical Status | Phase 1/2 | ||
| Clinical Description |
Phase 1/2 study of BDC-1001 as a single agent and in combination with nivolumab in patients with advanced HER2-expressing solid tumors.
|
||||
1711 (scFv)-SNAP-AuriF [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.52 uM
|
High EGFR expression (EGFR+++) | ||
| Method Description |
XTT viability assay was used to assess cytotoxicity following a 72 h incubation with 1711 (scFv)-SNAP-AuriF on MDA-MB-468.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
References